Jacobs Levy Equity Management Inc. Has $20.90 Million Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Jacobs Levy Equity Management Inc. lowered its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 6.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,138,704 shares of the biopharmaceutical company's stock after selling 72,610 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.68% of ACADIA Pharmaceuticals worth $20,895,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. SG Americas Securities LLC raised its stake in shares of ACADIA Pharmaceuticals by 380.3% in the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after buying an additional 1,966,607 shares in the last quarter. Barclays PLC raised its position in ACADIA Pharmaceuticals by 126.2% in the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock worth $4,269,000 after purchasing an additional 154,854 shares in the last quarter. Burney Co. bought a new position in ACADIA Pharmaceuticals during the fourth quarter worth about $6,953,000. Proficio Capital Partners LLC acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $272,000. Finally, Vanguard Group Inc. grew its stake in shares of ACADIA Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company's stock valued at $255,939,000 after purchasing an additional 104,444 shares during the period. Institutional investors and hedge funds own 96.71% of the company's stock.

ACADIA Pharmaceuticals Stock Performance

ACAD traded up $4.66 during mid-day trading on Friday, reaching $22.26. The stock had a trading volume of 17,783,924 shares, compared to its average volume of 1,915,725. The firm's fifty day simple moving average is $15.81 and its two-hundred day simple moving average is $17.02. The stock has a market capitalization of $3.72 billion, a P/E ratio of 28.54 and a beta of 0.47. ACADIA Pharmaceuticals Inc. has a 52 week low of $13.40 and a 52 week high of $25.06.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $244.32 million during the quarter, compared to analyst estimates of $239.32 million. During the same period last year, the company earned $0.10 earnings per share. The company's revenue was up 18.7% on a year-over-year basis. As a group, analysts expect that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on ACAD. StockNews.com lowered ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday. Cantor Fitzgerald restated an "overweight" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a "hold" rating and a $22.00 price target for the company. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $24.70.

Insider Buying and Selling

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the transaction, the director now directly owns 17,595 shares in the company, valued at $320,756.85. This trade represents a 21.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Mark C. Schneyer sold 3,171 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total value of $54,065.55. Following the completion of the sale, the executive vice president now owns 56,889 shares of the company's stock, valued at $969,957.45. This represents a 5.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,994 shares of company stock valued at $313,131 over the last ninety days. Insiders own 26.50% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.